Vitamin D and multiple sclerosis

Vitamin D

Volumn , Issue , 2011, Pages 1843-1877

  Hayes, Colleen E ^a   Nashold, Faye E ^a   Mayne, Christopher G ^b   Spanier, Justin A ^a   Nelson, Corwin D ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866184725     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10095-2     Document Type: Chapter

References (321)

1. Goldberg P. Multiple sclerosis: Vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: Sunlight, dietary factors and epidemiology. Int. J. Environm. Studies 1974, 6:19-27.
2. Schwartz G.G. Multiple sclerosis and prostate cancer: what do their similar geographies suggest?. Neuroepidemiology 1992, 11:244-254.
3. Hayes C.E., Cantorna M.T., DeLuca H.F. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 1997, 216:21-27.
4. Cantorna M.T., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 1996, 93:7861-7864.
5. Hill A.B. The environment and disease: association or causation?. Proc. R. Soc. Med. 1965, 58:295-300.
6. Acheson E.D., Bachrach C.A., Wright F.M. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiat. (Scand.) 1960, 35(Supplement 147):132-147.
7. Kurtzke J.F. On the fine structure of the distribution of multiple sclerosis. Acta Neurol. Scand. 1967, 43:257-282.
8. Ebers G.C., Sadovnick A.D. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology 1993, 12:1-5.
9. Swank R.L., Lerstad O., Strom A., Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 1952, 246:722-728.
10. Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol. Scand. 1970, 46:455-483.
11. Omdahl J.L., Morris H.A., B.K. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu. Rev. Nutr. May 2002, 22:139-166.
12. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 2004, 29:664-673.
13. Bhalla A.K., Amento E.P., Clemens T.L., Holick M.F., Krane S.M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 1983, 57:1308-1310.
14. Provvedini D.M., Tsoukas C.D., Deftos L.J., Manolagas S.C. 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983, 221:1181-1183.
15. Toell A., Polly P., Carlberg C. All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem. J. 352 Pt. 2000, 2:301-309.
16. Hayes C.E., Nashold F.E., Spach K.M., Pedersen L.B. The immunological functions of the vitamin D endocrine system. Cell Mol. Biol. (Noisy-le-grand) 2003, 49:277-300.
17. Hauser S.L., Oksenberg J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52:61-76.
18. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
19. Degenhardt A., Ramagopalan S.V., Scalfari A., Ebers G.C. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat. Rev. Neurol. 2009, 5:672-682.
20. Kremenchutzky M., Rice G.P., Baskerville J., Wingerchuk D.M., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006, 129:584-594.
21. Oksenberg J.R., Baranzini S.E., Sawcer S., Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. 2008, 9:516-526.
22. Oksenberg J.R., Baranzini S.E. Multiple sclerosis genetics-is the glass half full, or half empty?. Nat. Rev. Neurol. 2010, 6:429-437.
23. Baranzini S.E., Mudge J., van Velkinburgh J.C., Khankhanian P., Khrebtukova I., Miller N.A., et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010, 464:1351-1356.
24. Ebers G.C. Environmental factors and multiple sclerosis. Lancet Neurol. 2008, 7:268-277.
25. Ascherio A., Munger K.L. Epstein-Barr virus infection and multiple sclerosis: a review. J. Neuroimmune. Pharmacol. 2010, 5:271-277.
26. Lunemann J.D., Tintore M., Messmer B., Strowig T., Rovira A., Perkal H., et al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 2010, 67:159-169.
27. Levin L.I., Munger K.L., O'Reilly E.J., Falk K.I., Ascherio A. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann. Neurol. 2010, 67:824-830.
28. Alotaibi S., Kennedy J., Tellier R., Stephens D., Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004, 291:1875-1879.
29. Cree B.A., Reich D.E., Khan O., De Jager P.L., Nakashima I., Takahashi T., et al. Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA. Arch. Neurol. 2009, 66:226-233.
30. Lincoln M.R., Ramagopalan S.V., Chao M.J., Herrera B.M., Deluca G.C., Orton S.M., et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc. Natl. Acad. Sci. USA 2009, 106:7542-7547.
31. ?15 in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2009, 15:431-436.
32. ?15 in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2010, 16:127-128.
33. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007, 204:2899-2912.
34. Willis S.N., Stadelmann C., Rodig S.J., Caron T., Gattenloehner S., Mallozzi S.S., et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009, 132:3318-3328.
35. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 2002, 3:940-943.
36. Wucherpfennig K.W., Call M.J., Deng L., Mariuzza R. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr. Opin. Immunol. 2009, 21:590-595.
37. Salvetti M., Giovannoni G., Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr. Opin. Neurol. 2009, 22:201-206.
38. Hayes C.E., Donald Acheson E. A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10. Med. Hypoth. 2008, 71:85-90.
39. Spach K.M., Nashold F.E., Dittel B.N., Hayes C.E. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:6030-6037.
40. Hammond S.R., English D.R., McLeod J.G. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000, 123(Pt. 5):968-974.
41. van der Mei I.A., Ponsonby A.L., Blizzard L., Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001, 20:168-174.
42. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Simmons R., Taylor B.V., et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003, 327:316.
43. Islam T., Gauderman W.J., Cozen W., Mack T.M. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007, 69:381-388.
44. Kampman M.T., Wilsgaard T., Mellgren S.I. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 2007, 254:471-477.
45. Sloka J.S., Pryse-Phillips W.E., Stefanelli M. The relation of ultraviolet radiation and multiple sclerosis in Newfoundland. Can. J. Neurol. Sci. 2008, 35:69-74.
46. Beretich B.D., Beretich T.M. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2009, 15:891-898.
47. Auer D.P., Schumann E.M., Kumpfel T., Gossl C., Trenkwalder C. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 2000, 47:276-277.
48. Wuthrich R., Rieder H.P. The seasonal incidence of multiple sclerosis in Switzerland. Eur. Neurol. 1970, 3:257-264.
49. Bamford C.R., Sibley W.A., Thies C. Seasonal variation of multiple sclerosis exacerbations in Arizona. Neurology 1983, 33:697-701.
50. VanAmerongen B.M., Dijkstra C.D., Lips P., Polman C.H. Multiple sclerosis and vitamin D: an update. Eur. J. Clin. Nutr. 2004, 58:1095-1109.
51. Meier O.S., Balashar K.E., Healy B., Weiner H.L., Guttmann C.R. Seasonal prevalence of MS disease activity. Neurology 2010, 75:799-806.
52. Tremlett H., van der Mei I.A., Pittas F., Blizzard L., Paley G., Mesaros D., et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008, 31:271-279.
53. Dwyer T., van der Mei I., Ponsonby A.L., Taylor B.V., Stankovich J., McKay J.D., et al. Melanocortin 1 receptor genotype, past environmental sun exposure, and risk of multiple sclerosis. Neurology 2008, 71:583-589.
54. Ascherio A., Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Sem. Neurol. 2008, 28:17-28.
55. Smolders J., Damoiseaux J., Menheere P., Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J. Neuroimmunol. 2008, 194:7-17.
56. Ascherio A., Munger K.L., Simon K.C. Vitamin D and multiple sclerosis. Lancet Neurol. 2010, 9:599-612.
57. Zerwekh J.E. Blood biomarkers of vitamin D status. Am. J. Clin. Nutr. 2008, 87:1087S-1091S.
58. Lips P., Chapuy M.C., Dawson-Hughes B., Pols H.A., Holick M.F. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos. Int. 1999, 9:394-397.
59. Hollis B.W. Measuring 25-hydroxyvitamin D in a clinical environment: challenges and needs. Am. J. Clin. Nutr. 2008, 88:507S-510S.
60. Holick M.F. Vitamin D: a millennium perspective. J. Cell Biochem. 2003, 88:296-307.
61. Ebers G. Month of birth and multiple sclerosis risk in Scotland. Eur. Neurol. 2010, 63:41-42.
62. Clemens T.L., Adams J.S., Henderson S.L., Holick M.F. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982, 1:74-76.
63. Bell N.H., Greene A., Epstein S., Oexmann M.J., Shaw S., Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J. Clin. Invest. 1985, 76:470-473.
64. Bell N.H. Bone and mineral metabolism in African Americans. Trends Endocrinol. Metab. 1997, 8:240-245.
65. Chen T.C., Chimeh F., Lu Z., Mathieu J., Person K.S., Zhang A., et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch. Biochem. Biophys. 2007, 460:213-217.
66. Orton S.M., Morris A.P., Herrera B.M., Ramagopalan S.V., Lincoln M.R., Chao M.J., et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am. J. Clin. Nutr. 2008, 88:441-447.
67. Fu L., Yun F., Oczak M., Wong B.Y., Vieth R., Cole D.E. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH)D] to vitamin D supplementation. Clin. Biochem. 2009, 42:1174-1177.
68. Ahn J., Yu K., Stolzenberg-Solomon R., Simon K.C., McCullough M.L., Gallicchio L., et al. Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet. 2010, 19:2739-2745.
69. Cosman F., Nieves J., Herbert J., Shen V., Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J. Bone Miner. Res. 1994, 9:1097-1105.
70. Nieves J., Cosman F., Herbert J., Shen V., Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994, 44:1687-1692.
71. Cosman F., Nieves J., Komar L., Ferrer G., Herbert J., Formica C., et al. Fracture history and bone loss in patients with MS. Neurology 1998, 51:1161-1165.
72. Terzi T., Terzi M., Tander B., Canturk F., Onar M. Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J. Clin. Neurosci. 2010, 17:1260-1264.
73. Ozgocmen S., Bulut S., Ilhan N., Gulkesen A., Ardicoglu O., Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J. Bone Miner. Metab. 2005, 23:309-313.
74. van der Mei I.A., Ponsonby A.L., Dwyer T., Blizzard L., Taylor B.V., Kilpatrick T., et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 2007, 254:581-590.
75. Hiremath G.S., Cettomai D., Baynes M., Ratchford J.N., Newsome S., Harrison D., et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2009, 15:735-740.
76. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J. Neurol. 2009, 256:1468-1479.
77. Barnes M.S., Bonham M.P., Robson P.J., Strain J.J., Lowe-Strong A.S., Eaton-Evans J., et al. Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Multiple Sclerosis (Houndmills, Basingstoke, England) 2007, 13:670-672.
78. Munger K.L., Zhang S.M., O'Reilly E., Hernan M.A., Olek M.J., Willett W.C., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
79. Munger K.L., Levin L.I., Hollis B.W., Howard N.S., Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
80. Lucas R.M., Ponsonby A.L., Dear K., Valery P.C., Pender M.P., Taylor B.U., et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011, 76:540-548.
81. Kragt J., van Amerongen B., Killestein J., Dijkstra C., Uitdehaag B., Polman C., et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Multiple Sclerosis (Houndmills, Basingstoke, England) 2009, 15:9-15.
82. Hine T.J., Roberts N.B. Seasonal variation in serum 25-hydroxy vitamin D3 does not affect 1,25-dihydroxy vitamin D. Ann. Clin. Biochem. 1994, 31(Pt. 1):31-34.
83. Embry A.F., Snowdon L.R., Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann. Neurol. 2000, 48:271-272.
84. Soilu-Hanninen M., Laaksonen M., Laitinen I., Eralinna J.P., Lilius E.M., Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J. Neurol. Neurosurg. Psychiat. 2008, 79:152-157.
85. Rovaris M., Comi G., Sormani M.P., Wolinsky J.S., Ladkani D., Filippi M. Effects of seasons on magnetic resonance imaging - measured disease activity in patients with multiple sclerosis. Ann. Neurol. 2001, 49:415-416.
86. Killestein J., Rep M.H., Meilof J.F., Ader H.J., Uitdehaag B.M., Barkhof F., et al. Seasonal variation in immune measurements and MRI markers of disease activity in MS. Neurology 2002, 58:1077-1080.
87. Mowry E.M., Krupp L.B., Milazzo M., Chabas D., Strober J.B., Belman A.L., et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann. Neurol. 2010, 67:618-624.
88. Simpson S., Taylor B., Blizzard L., Ponsonby A.-L., Pittas F., Tremlett H., et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann. neurol. 2010, 68:193-203.
89. Soilu-Hanninen M., Airas L., Mononen I., Heikkila A., Viljanen M., Hanninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2005, 11:266-271.
90. Correale J., Ysrraelit M.C., Gaitan M.I. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009, 132:1146-1160.
91. Smolders J., Menheere P., Kessels A., Damoiseaux J., Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2008, 14:1220-1224.
92. Holmoy T., Moen S.M., Gundersen T.A., Holick M.F., Fainardi E., Castellazzi M., et al. 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2009, 15:1280-1285.
93. Mahon B.D., Gordon S.A., Cruz J., Cosman F., Cantorna M.T. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J. Neuroimmunol. 2003, 134:128-132.
94. Kimball S.M., Ursell M.R., O'Connor P., Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am. J. Clin. Nutr. 2007, 86:645-651.
95. Burton J.M., Kimball S., Vieth R., Bar-Or A., Dosch H.M., Cheung R., et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74:1852-1859.
96. Fugger L., Friese M.A., Bell J.I. From genes to function: the next challenge to understanding multiple sclerosis. Nat. Rev. Immunol. 2009, 9:408-417.
97. ?1501 is regulated by vitamin D. PLoS Genetics 2009, 5:e1000369.
98. Ramagopalan S.V., Ebers G.C. Multiple sclerosis: major histocompatibility complexity and antigen presentation. Genome Med. 2009, 1:105.
99. Okuda D.T., Srinivasan R., Oksenberg J.R., Goodin D.S., Baranzini S.E., Beheshtian A., et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain 2009, 132:250-259.
100. Dyment D.A., Cader M.Z., Herrera B.M., Ramagopalan S.V., Orton S.M., Chao M., et al. A genome scan in a single pedigree with a high prevalence of multiple sclerosis. J. Neurol. Neurosurg. Psychiat. 2008, 79:158-162.
101. Ramagopalan S.V., Ebers G.C. Epistasis: multiple sclerosis and the major histocompatibility complex. Neurology 2009, 72:566-567.
102. Zierold C., Darwish H.M., DeLuca H.F. Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. J. Biol. Chem. 1995, 270:1675-1678.
103. Ramagopalan S.V., Heger A., Berlanga A.J., Maugeri N.J., Lincoln M.R., Burrell A., et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Research 2010, http://www.genome.org/cgi/doi/10.1101/gr.107920.110.
104. ?15. Neurology 2010, 74:1905-1910.
105. Zinkernagel R.M., Doherty P.C. The discovery of MHC restriction. Immunol. Today 1997, 18:14-17.
106. Anderson G., Lane P.J., Jenkinson E.J. Generating intrathymic microenvironments to establish T-cell tolerance. Nat. Rev. Immunol. 2007, 7:954-963.
107. Irla M., Hollander G., Reith W. Control of central self-tolerance induction by autoreactive CD4+ thymocytes. Trends Immunol. 2010, 31:71-79.
108. Bayes H.K., Weir C.J., O'Leary C. Timing of birth and risk of multiple sclerosis in the Scottish population. Eur. Neurol. 2010, 63:36-40.
109. Ramagopalan S.V., Link J., Byrnes J.K., Dyment D.A., Giovannoni G., Hintzen R.Q., et al. HLA-DRB1 and month of birth in multiple sclerosis. Neurology 2009, 73:2107-2111.
110. Islam T., Gauderman W.J., Cozen W., Hamilton A.S., Burnett M.E., Mack T.M. Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann. Neurol. 2006, 60:56-64.
111. Dickinson J., Perera D., van der Mei A., Ponsonby A.L., Polanowski A., Thomson R., et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Multiple Sclerosis (Houndmills, Basingstoke, England) 2009, 15:563-570.
112. Smolders J., Peelen E., Thewissen M., Menheere P., Cohen Tervaert J.W., Hupperts R., et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun. Rev. 2009, 8:621-626.
113. Fukazawa T., Yabe I., Kikuchi S., Sasaki H., Hamada T., Miyasaka K., et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J. Neurol. Sci. 1999, 166:47-52.
114. Niino M., Fukazawa T., Yabe I., Kikuchi S., Sasaki H., Tashiro K. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J. Neurol. Sci. 2000, 177:65-71.
115. Tajouri L., Ovcaric M., Curtain R., Johnson M.P., Griffiths L.R., Csurhes P., et al. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J. Neurogenet. 2005, 19:25-38.
116. Steckley J.L., Dyment D.A., Sadovnick A.D., Risch N., Hayes C., Ebers G.C. Genetic analysis of vitamin D related genes in Canadian multiple sclerosis patients. Canadian Collaborative Study Group. Neurology 2000, 54:729-732.
117. Yeo T.W., Maranian M., Singlehurst S., Gray J., Compston A., Sawcer S. Four single nucleotide polymorphisms from the vitamin D receptor gene in UK multiple sclerosis. J. Neurol. 2004, 251:753-754.
118. Simon K.C., Munger K.L., Xing Y., Ascherio A. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2010, 16:133-138.
119. Vitale E., Cook S., Sun R., Specchia C., Subramanian K., Rocchi M., et al. Linkage analysis conditional on HLA status in a large North American pedigree supports the presence of a multiple sclerosis susceptibility locus on chromosome 12p12. Hum. Mol. Genet. 2002, 11:295-300.
120. Gross C., Krishnan A.V., Malloy P.J., Eccleshall T.R., Zhao X.Y., Feldman D. The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J. Bone Miner. Res. 1998, 13:1691-1699.
121. Arai H., Miyamoto K., Taketani Y., Yamamoto H., Iemori Y., Morita K., et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 1997, 12:915-921.
122. Jurutka P.W., Remus L.S., Whitfield G.K., Thompson P.D., Hsieh J.C., Zitzer H., et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 2000, 14:401-420.
123. Partridge J.M., Weatherby S.J., Woolmore J.A., Highland D.J., Fryer A.A., Mann C.L., et al. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology 2004, 62:2323-2325.
124. Mamutse G., Woolmore J., Pye E., Partridge J., Boggild M., Young C., et al. Vitamin D receptor gene polymorphism is associated with reduce disability in multiple sclerosis. Multiple Sclerosis 2008, 14:1280-1283.
125. Smolders J., Damoiseaux J., Menheere P., Tervaert J.W., Hupperts R. Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J. Neuroimmunol. 2009, 207:117-121.
126. Arai H., Miyamoto K.I., Yoshida M., Yamamoto H., Taketani Y., Morita K., et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. 2001, 16:1256-1264.
127. Torkildsen O., Knappskog P.M., Nyland H.I., Myhr K.M. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch. Neurol. 2008, 65:809-811.
128. Sakaki T., Kagawa N., Yamamoto K., Inouye K. Metabolism of vitamin D3 by cytochromes P450. Front. Biosci. 2005, 10:119-134.
129. Yamamoto K., Uchida E., Urushino N., Sakaki T., Kagawa N., Sawada N., et al. Identification of the amino acid residue of CYP27B1 responsible for binding of 25-hydroxyvitamin D3 whose mutation causes vitamin D-dependent rickets type 1. J. Biol. Chem. 2005, 280:30511-30516.
130. Ramagopalan S.V., Hanwell H.E., Giovannoni G., Knappskog P.M., Nyland H.I., Myhr K.M., et al. Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis. Arch. Neurol. 2010, 67:1034-1035.
131. ANZgene, and A. a. N.Z.M.S.G. Consortium. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nature Gen. 41 (2009) 824-828.
132. Sundqvist E., Baarnhieln M., Alfredsson L., Hillert J., Olsson T., Kockum I. Confirmation of association between multiple sclerosis and CYP27B1. Eur. J. Human Genet. 2010, 18:1349-1352.
133. Xu C., Dai Y., Lorentzen J.C., Dahlman I., Olsson T., Hillert J. Linkage analysis in multiple sclerosis of chromosomal regions syntenic to experimental autoimmune disease loci. Eur. J. Hum. Genet. 2001, 9:458-463.
134. Speeckaert M., Huang G., Delanghe J.R., Taes Y.E. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin. Chim. Acta 2006, 372:33-42.
135. van Hoof H.J., de Sevaux R.G., van Baelen H., Swinkels L.M., Klipping C., Ross H.A., et al. Relationship between free and total 1,25-dihydroxyvitamin D in conditions of modified binding. Eur. J. Endocrinol. 2001, 144:391-396.
136. Hollsberg P., Haahr S., Larsen P.M., Fey S.J. MS and the group-specific component. Acta. Neurol. Scand. 1988, 78:158-160.
137. Lindblom B., Wetterling G., Link H. Distribution of group-specific component subtypes in multiple sclerosis. Acta Neurol. Scand. 1988, 78:443-444.
138. Niino M., Kikuchi S., Fukazawa T., Yabe I., Tashiro K. No association of vitamin D-binding protein gene polymorphisms in Japanese patients with MS. J. Neuroimmunol. 2002, 127:177-179.
139. Di Bacco M., Luiselli D., Manca M.L., Siciliano G. Bayesian approach to searching for susceptibility genes: Gc2 and EsD1 alleles and multiple sclerosis. Coll. Antropol. 2002, 26:77-84.
140. Rithidech K.N., Honikel L., Milazzo M., Madigan D., Troxell R., Krupp L.B. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Multiple Sclerosis (Houndmills, Basingstoke, England) 2009, 15:455-464.
141. Dumont D., Noben J.P., Raus J., Stinissen P., Robben J. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4:2117-2124.
142. Qin Z., Qin Y., Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol. Neurobiol. 2009, 29:203-210.
143. Lehmensiek V., Sussmuth S.D., Tauscher G., Brettschneider J., Felk S., Gillardon F., et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2007, 13:840-849.
144. Ottervald J., Franzen B., Nilsson K., Andersson L.I., Khademi M., Eriksson B., et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J. Proteomics 2010, 73:1117-1132.
145. Stoop M.P., Dekker L.J., Titulaer M.K., Burgers P.C., Sillevis Smitt P.A., Luider T.M., et al. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8:1576-1585.
146. Tumani H., Lehmensiek V., Rau D., Guttmann I., Tauscher G., Mogel H., et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci. Lett. 2009, 452:214-217.
147. Comabella M., Fernandez M., Martin R., Rivera-Vallve S., Borras E., Chiva C., et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133:1082-1093.
148. Holmoy T., Moen S.M. Assessing vitamin D in the central nervous system. Acta Neurol. Scand. Suppl. 2010, 88-92.
149. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
150. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
151. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
152. Wolf A., Kabat E.A., Bezer A.E. The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease. J. Neuropathol. Exp. Neurol. 1947, 6:333-357.
153. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1:242-248.
154. Lublin F.D., Lavasa M., Viti C., Knobler R.L. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol. Immunopathol. 1987, 45:122-128.
155. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
156. Yu M., Nishiyama A., Trapp B.D., Tuohy V.K. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1996, 64:91-100.
157. The IFNB Multiple Sclerosis Study Group, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
158. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504.
159. Faria A.M., Weiner H.L. Oral tolerance. Immunol. Rev. 2005, 206:232-259.
160. Katsara M., Minigo G., Plebanski M., Apostolopoulos V. The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert. Opin. Biol. Ther. 2008, 8:1873-1884.
161. Lemire J.M., Archer D.C. 1,25-Dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 1991, 87:1103-1107.
162. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2002, 2:85-95.
163. Branisteanu D.D., Waer M., Sobis H., Marcelis S., Vandeputte M., Bouillon R. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J. Neuroimmunol. 1995, 61:151-160.
164. Nashold F.E., Hoag K.A., Goverman J., Hayes C.E. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2001, 119:16-29.
165. 3 acts directly on the T lymphocyte to vitamin D receptor to inhibit experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2011, 41:822-832.
166. Spach K.M., Hayes C.E. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 2005, 175:4119-4126.
167. Nashold F.E., Spach K.M., Spanier J.A., Hayes C.E. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J. Immunol. 2009, 183:3672-3681.
168. Suen W.E., Bergman C.M., Hjelmstrom P., Ruddle N.H. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Med. 1997, 186:1233-1240.
169. Becklund B.R., Severson K.S., Vang S.V., DeLuca H.F. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc. Natl. Acad. Sci. USA 2010, 107:6418-6423.
170. Hauser S.L., Weiner H.L., Che M., Shapiro M.E., Gilles F., Letvin N.L. Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. J. Immunol. 1984, 132:1276-1281.
171. Tsunoda I., Kuang L.Q., Igenge I.Z., Fujinami R.S. Converting relapsing remitting to secondary progressive experimental allergic encephalomyelitis (EAE) by ultraviolet B irradiation. J. Neuroimmunol. 2005, 160:122-134.
172. Loser K., Beissert S. Regulation of cutaneous immunity by the environment: an important role for UV irradiation and vitamin D. Int. Immunopharmacol. 2009, 9:587-589.
173. Ghoreishi M., Bach P., Obst J., Komba M., Fleet J.C., Dutz J.P. Expansion of antigen-specific regulatory T cells with the topical vitamin D analog calcipotriol. J. Immunol. 2009, 182:6071-6078.
174. Handunnetthi L., Ramagopalan S.V. UV radiation, vitamin D, and multiple sclerosis. Proc. Natl. Acad. Sci. USA 2010, 107:E130.
175. Cantorna M.T., Humpal-Winter J., DeLuca H.F. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J. Nutr. 1999, 129:1966-1971.
176. Meehan T.F., Vanhooke J., Prahl J., Deluca H.F. Hypercalcemia produced by parathyroid hormone suppresses experimental autoimmune encephalomyelitis in female but not male mice. Arch. Biochem. Biophys. 2005, 442:214-221.
177. Becklund B.R., Hansen D.W., Deluca H.F. Enhancement of 1,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis by calcitonin. Proc. Natl. Acad. Sci. USA 2009, 106:5276-5281.
178. Becklund B.R., James B.J., Gagel R.F., DeLuca H.F. The calcitonin/calcitonin gene related peptide-alpha gene is not required for 1alpha,25-dihydroxyvitamin D3-mediated suppression of experimental autoimmune encephalomyelitis. Arch. Biochem. Biophys. 2009, 488:105-108.
179. Harrell G.T., Fisher S. Blood chemical changes in Boeck's sarcoid with particular reference to protein, calcium and phosphatase values. J. Clin. Invest. 1939, 18:687-693.
180. Papapoulos S.E., Clemens T.L., Fraher L.J., Lewin I.G., Sandler L.M., O'Riordan J.L. 1,25-dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet 1979, 1:627-630.
181. Bell N.H., Stern P.H., Pantzer E., Sinha T.K., DeLuca H.F. Evidence that increased circulating 1 alpha, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J. Clin. Invest. 1979, 64:218-225.
182. Adams J.S., Sharma O.P., Gacad M.A., Singer F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J. Clin. Invest. 1983, 72:1856-1860.
183. Adams J.S., Gacad M.A. Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J. Exp. Med. 1985, 161:755-765.
184. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001, 86:888-894.
185. Hewison M., Burke F., Evans K.N., Lammas D.A., Sansom D.M., Liu P., et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J. Steroid Biochem. Mol. Biol. 2007, 103:316-321.
186. Adams J.S., Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:80-90.
187. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol. Cell Endocrinol. 2010, 321:103-111.
188. Heine G., Niesner U., Chang H.D., Steinmeyer A., Zugel U., Zuberbier T., et al. 1,25-Dihydroxyvitamin D(3) promotes IL-10 production in human B cells. Eur. J. Immunol. 2008, 38:2210-2218.
189. Sigmundsdottir H., Pan J., Debes G.F., Alt C., Habtezion A., Soler D., et al. DCs metabolize sunlight-induced vitamin D3 to "program" T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 2007, 8:285-293.
190. Enioutina E.Y., Bareyan D., Daynes R.A. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses. J. Immunol. 2009, 182:4296-4305.
191. Neveu I., Naveilhan P., Menaa C., Wion D., Brachet P., Garabedian M. Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. J. Neurosci. Res. 1994, 38:214-220.
192. Anderson P.H., Hendrix I., Sawyer R.K., Zarrinkalam R., Manvis J., Sarvestani G.T., et al. Co-expression of C'YP27B1 enzyme with the 1.5 kb CYP27B1 promoter-luciferase transgene in the mouse. Mol. Cell Endocrinol. 2008, 285:1-9.
193. Meehan T.F., DeLuca H.F. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch. Biochem. Biophys. 2002, 408:200-204.
194. Brennan A., Katz D.R., Nunn J.D., Barker S., Hewison M., Fraher L.J., et al. Dendritic cells from human tissues express receptors for the immunoregulatory vitamin D3 metabolite, dihydroxycholecalciferol. Immunology 1987, 61:457-461.
195. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179:1634-1647.
196. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374:334-338.
197. Meehan T.F., DeLuca H.F. CD8(+) T cells are not necessary for 1 alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Proc. Natl. Acad. Sci. USA 2002, 99:5557-5560.
198. Mattner F., Smiroldo S., Galbiati F., Muller M., Di Lucia P., Poliani P.L., et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D(3). Eur. J. Immunol. 2000, 30:498-508.
199. Muthian G., Raikwar H.P., Rajasingh J., Bright J.J. 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J. Neurosci. Res. 2006, 83:1299-1309.
200. Muller K., Gram J., Bollerslev J., Diamant M., Barington T., Hansen M.B., et al. Down-regulation of monocyte functions by treatment of healthy adults with 1 alpha,25 dihydroxyvitamin D3. Int. J. Immunopharmacol. 1991, 13:525-530.
201. Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 1998, 160:5314-5319.
202. Cantorna M.T., Humpal-Winter J., DeLuca H.F. In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3). Arch. Biochem. Biophys. 2000, 377:135-138.
203. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
204. Tang J., Zhou R., Luger D., Zhu W., Silver P.B., Grajewski R.S., et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J. Immunol. 2009, 182:4624-4632.
205. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 2008, 324:23-33.
206. Sakaguchi S., Ono M., Setoguchi R., Yagi H., Hori S., Fehervari Z., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006, 212:8-27.
207. Correale J., Gilmore W., Lopez J., Li S.Q., McMillan M., Weiner L.P. Defective post-thymic tolerance mechanisms during the chronic progressive stage of multiple sclerosis. Nat. Med. 1996, 2:1354-1360.
208. Frisullo G., Nociti V., Iorio R., Patanella A.K., Caggiula M., Marti A., et al. Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology 2009, 127:418-428.
209. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
210. Astier A.L., Meiffren G., Freeman S., Hafler D.A. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006, 116:3252-3257.
211. Martinez-Forero I., Garcia-Munoz R., Martinez-Pasamar S., Inoges S., Lopez-Diaz de Cerio A., Palacios R., et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur. J. Immunol. 2008, 38:576-586.
212. Haas J., Fritzsching B., Trubswetter P., Korporal M., Milkova L., Fritz B., et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J. Immunol. 2007, 179:1322-1330.
213. Venken K., Hellings N., Broekmans T., Hensen K., Rummens J.L., Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J. Immunol. 2008, 180:6411-6420.
214. Venken K., Hellings N., Liblau R., Stinissen P. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 2010, 16:58-68.
215. Royal W., Mia Y., Li H., Naunton K. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J. Neuroimmunol. 2009, 213:135-141.
216. Smolders J., Thewissen M., Peelen E., Menheere P., Cohen Tervaert J.W., Damoiseaux J., et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009, 4:e6635.
217. Smolders J., Menheere P., Thewissen M., Peelen E., Tervaert J.W., Hupperts R., et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2010, 121:243-246.
218. Swierkosz J.E., Swanborg R.H. Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis. J. Immunol. 1975, 115:631-633.
219. Karpus W.J., Swanborg R.H. CD4+ suppressor cells differentially affect the production of IFN-gamma by effector cells of experimental autoimmune encephalomyelitis. J. Immunol. 1989, 143:3492-3497.
220. Suri-Payer E., Amar A.Z., Thornton A.M., Shevach E.M. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 1998, 160:1212-1218.
221. Olivares-Villagomez D., Wang Y., Lafaille J.J. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 1998, 188:1883-1894.
222. Van de Keere F., Tonegawa S. CD4(+) T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J. Exp. Med. 1998, 188:1875-1882.
223. McGeachy M.J., Stephens L.A., Anderton S.M. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 2005, 175:3025-3032.
224. Hori S., Haury M., Coutinho A., Demengeot J. Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc. Natl. Acad. Sci. USA 2002, 99:8213-8218.
225. Bettelli E., Das M.P., Howard E.D., Weiner H.L., Sobel R.A., Kuchroo V.K. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 1998, 161:3299-3306.
226. Stohlman S.A., Pei L., Cua D.J., Li Z., Hinton D.R. Activation of regulatory cells suppresses experimental allergic encephalomyelitis via secretion of IL-10. J. Immunol. 1999, 163:6338-6344.
227. Burkhart C., Liu G.Y., Anderton S.M., Metzler B., Wraith D.C. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int. Immunol. 1999, 11:1625-1634.
228. Sundstedt A., O'Neill E.J., Nicolson K.S., Wraith D.C. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. 2003, 170:1240-1248.
229. Zhang X., Koldzic D.N., Izikson L., Reddy J., Nazareno R.F., Sakaguchi S., et al. IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int. Immunol. 2004, 16:249-256.
230. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 2002, 195:603-616.
231. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
232. Moore K.W., Vieira P., Fiorentino D.F., Trounstine M.L., Khan T.A., Mosmann T.R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990, 248:1230-1234.
233. Yoon S.I., Jones B.C., Logsdon N.J., Walter M.R. Same structure, different function crystal structure of the Epstein-Barr virus IL-10 bound to the soluble IL-10R1 chain. Structure 2005, 13:551-564.
234. Moore F., Buonocore S., Paulart F., Thielemans K., Goldman M., Flamand V. Unexpected effects of viral interleukin-10-secreting dendritic cells in vivo: preferential inhibition of TH2 responses. Transplant. Proc. 2004, 36:3260-3266.
235. Li M.O., Flavell R.A. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 2008, 28:468-476.
236. Griffin M.D., Dong X., Kumar R. Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch. Biochem. Biophys. 2007, 460:218-226.
237. Adorini L., Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 2009, 70:345-352.
238. Xu H., Soruri A., Gieseler R.K., Peters J.H. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand. J. Immunol. 1993, 38:535-540.
239. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
240. van Halteren A.G., van Etten E., de Jong E.C., Bouillon R., Roep B.O., Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 2002, 51:2119-2125.
241. Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2001, 98:6800-6805.
242. Dong X., Craig T., Xing N., Bachman L.A., Paya C.V., Weih F., et al. Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J. Biol. Chem. 2003, 278:49378-49385.
243. D'Ambrosio D., Cippitelli M., Cocciolo M.G., Mazzeo D., Di Lucia P., Lang R., et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J. Clin. Invest. 1998, 101:252-262.
244. Penna G., Amuchastegui S., Giarratana N., Daniel K.C., Vulcano M., Sozzani S., et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol. 2007, 178:145-153.
245. Gregori S., Giarratana N., Smiroldo S., Uskokovic M., Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1367-1374.
246. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006, 176:6752-6761.
247. Curti A., Pandolfi S., Valzasina B., Aluigi M., Isidori A., Ferri E., et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007, 109:2871-2877.
248. Spach K.M., Pedersen L.B., Nashold F.E., Kayo T., Yandell B.S., Prolla T.A., et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol. Genomics 2004, 18:141-151.
249. Pedersen L.B., Nashold F.E., Spach K.M., Hayes C.E. 1,25-Dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J. Neurosci. Res. 2007, 85:2480-2490.
250. Nataf S., Garcion E., Darcy F., Chabannes D., Muller J.Y., Brachet P. 1,25-Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J. Neuropathol. Exp. Neurol. 1996, 55:904-914.
251. Garcion E., Sindji L., Nataf S., Brachet P., Darcy F., Montero-Menei C.N. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta. Neuropathol. 2003, 105:438-448.
252. Nashold F.E., Miller D.J., Hayes C.E. 1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2000, 103:171-179.
253. Pender M.P., Rist M.J. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia 2001, 36:137-144.
254. Bronte V., Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005, 5:641-654.
255. Sarin A., Nakajima H., Henkart P.A. A protease-dependent TCR-induced death pathway in mature lymphocytes. J. Immunol. 1995, 154:5806-5812.
256. Decallonne B., Mathieu C. Defective activation-induced cell death in NOD T lymphocytes: 1,25-dihydroxyvitamin D3 restores defect. Ann. NY. Acad. Sci. 2003, 1005:176-177.
257. Wust S., van den Brandt J., Tischner D., Kleiman A., Tuckermann J.P., Gold R., et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J. Immunol. 2008, 180:8434-8443.
258. Rebenko-Moll N.M., Liu L., Cardona A., Ransohoff R.M. Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details. Curr. Opin. Immunol. 2006, 18:683-689.
259. Gysemans C.A., Cardozo A.K., Callewaert H., Giulietti A., Hulshagen L., Bouillon R., et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005, 146:1956-1964.
260. Encinas J.M., Manganas L., Enikolopov G. Nitric oxide and multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2005, 5:232-238.
261. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-urniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 1998, 339:285-291.
262. Kovacs C.S., Kronenberg H.M. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr. Rev. 1997, 18:832-872.
263. Elenkov I.J., Wilder R.L., Bakalov V.K., Link A.A., Dimitrov M.A., Fisher S., et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab. 2001, 86:4933-4938.
264. Schwartz G.G. Hypothesis: calcitriol mediates pregnancy's protective effect on multiple sclerosis. Arch. Neurol. 1993, 50:455.
265. Stumpf W.E., Denny M.E. Vitamin D (soltriol), light, and reproduction. Am. J. Obstet. Gynecol. 1989, 161:1375-1384.
266. Halloran B.P., DeLuca H.F. Effect of vitamin D deficiency on fertility and reproductive capacity in the female rat. J. Nutr. 1980, 110:1573-1580.
267. Panda D.K., Miao D., Tremblay M.L., Sirois J., Farookhi R., Hendy G.N., et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. USA 2001, 98:7498-7503.
268. Seavey M.M., Mosmann T.R. Immunoregulation of fetal and anti-paternal immune responses. Immunol. Res. 2008, 40:97-113.
269. Novakovic B., Sibson M., Ng H.K., Manuelpillai U., Rakyan V., Down T., et al. Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface. J. Biol. Chem. 2009, 284:14838-14848.
270. Rebut-Bonneton C., Demignon J. Effects of 1,25-dihydroxyvitamin D3 on in vitro lymphocyte reactions: arguments for a role at the maternofetal interface. Gynecol. Obstet. Invest. 1991, 32:134-138.
271. Whitacre C.C. Sex differences in autoimmune disease. Nat. Immunol. 2001, 2:777-780.
272. Koch-Henriksen N., Sorensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010, 9:520-532.
273. Acheson E.D. Epidemiology of multiple sclerosis. Br. Med. Bull 1977, 33:9-14.
274. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006, 5:932-936.
275. Roger E., Duquette P. Multiple sclerosis: increase over time in the ratio of women to men in patients with an early onset. Multiple Sclerosis 2008, 14:S63.
276. Noonan C.W., Kathman S.J., White M.C. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002, 58:136-138.
277. Wallin M.T., Page W.F., Kurtzke J.F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 2004, 55:65-71.
278. Simmons R.D., Hall C.A., Gleeson P., Everard G., Casse R.F., O'Brien E.D. Prevalence survey of multiple sclerosis in the Australian Capital Territory. Intern. Med. J. 2001, 31:161-167.
279. Alonso A., Hernan M.A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008, 71:129-135.
280. Hirst C., Ingram G., Pickersgill T., Swingler R., Compston D.A., Robertson N.P. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J. Neurol. Neurosurg. Psychiat. 2009, 80:386-391.
281. Midgard R., Riise T., Svanes C., Kvale G., Nyland H. Incidence of multiple sclerosis in More and Romsdal, Norway from 1950 to 1991. An age-period-cohort analysis. Brain 1996, 119(Pt. 1):203-211.
282. Grytten N., Glad S.B., Aarseth J.H., Nyland H., Midgard R., Myhr K.M. A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. Neurology 2006, 66:182-186.
283. Pugliatti M., Sotgiu S., Solinas G., Castiglia P., Pirastru M.I., Murgia B., et al. Multiple sclerosis epidemiology in Sardinia: evidence for a true increasing risk. Acta. Neurol. Scand. 2001, 103:20-26.
284. Ramagopalan S.V., Byrnes J.K., Orton S.M., Dyment D.A., Guimond C., Yee I.M., et al. Sex ratio of multiple sclerosis and clinical phenotype. Eur. J. Neurol. 2009, 17:634-637.
285. Herrera B.M., Cader M.Z., Dyment D.A., Bell J.T., Deluca G.C., Willer C.J., et al. Multiple sclerosis susceptibility and the X chromosome. Multiple Sclerosis (Houndmills, Basingstoke, England) 2007, 13:856-864.
286. Thomas T., Banwell B. Multiple sclerosis in children. Sem. Neurol. 2008, 28:69-83.
287. Voskuhl R.R., Palaszynski K. Sex hormones in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neuroscientist 2001, 7:258-270.
288. Soldan S.S., Alvarez Retuerto A.I., Sicotte N.L., Voskuhl R.R. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol. 2003, 171:6267-6274.
289. Offner H., Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann. NY. Acad. Sci. 2006, 1089:343-372.
290. Sicotte N.L., Giesser B.S., Tandon V., Klutch R., Steiner B., Drain A.E., et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch. Neurol. 2007, 64:683-688.
291. Gold S.M., Chalifoux S., Giesser B.S., Voskuhl R.R. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J. Neuroinflamm. 2008, 5:32.
292. Kinuta K., Tanaka H., Moriwake T., Aya K., Kato S., Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 2000, 141:1317-1324.
293. Barrera D., Avila E., Hernandez G., Halhali A., Biruete B., Larrea F., et al. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J. Steroid Biochem. Mol. Biol. 2007, 103:529-532.
294. Yague J.G., Garcia-Segura L.M., Azcoitia I. Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells. Endocrine 2009, 35:252-261.
295. Aarskog D., Aksnes L., Markestad T., Rodland O. Effect of estrogen on vitamin D metabolism in tall girls. J. Clin. Endocrinol. Metab. 1983, 57:1155-1158.
296. Liel Y., Shany S., Smirnoff P., Schwartz B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 1999, 140:280-285.
297. Schwartz B., Smirnoff P., Shany S., Liel Y. Estrogen controls expression and bioresponse of 1,25-dihydroxyvitamin D receptors in the rat colon. Mol. Cell Biochem. 2000, 203:87-93.
298. Zhou Y., Ye R.Q., Cai D.H., Zhang H. Effect of estrogen and progesterone on the expression of 1,25-dihydroxyvitamin D receptors mRNA in the liver of ovariectomized rats. Di 1 jun. yi da xue xue bao = Acad. J. First Medical College of PLA 2002, 22:521-523.
299. Escaleira M.T., Sonohara S., Brentani M.M. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J. Steroid Biochem. Mol. Biol. 1993, 45:257-263.
300. Byrne I.M., Flanagan L., Tenniswood M.P., Welsh J. Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 2000, 141:2829-2836.
301. Smith R., Studd J.W. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J. R. Soc. Med. 1992, 85:612-613.
302. Holmqvist P., Wallberg M., Hammar M., Landtblom A.M., Brynhildsen J. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 2006, 54:149-153.
303. Vegeto E., Benedusi V., Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol. 2008, 29:507-519.
304. Orton S.M., Ramagopalan S.V., Brocklebank D., Herrera B.M., Dyment D.A., Yee I.M., et al. Effect of immigration on multiple sclerosis sex ratio in Canada: the Canadian Collaborative Study. J. Neurol. Neurosurg. Psychiat. 2010, 81:31-36.
305. Achiron A., Barak Y., Miron S., Izhak Y., Faibel M., Edelstein S. Alfacalcidol treatment in multiple sclerosis. Clin. Neuropharmacol. 2003, 26:53.
306. Wingerchuk D.M., Lesaux J., Rice G.P., Kremenchutzky M., Ebers G.C. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiat. 2005, 76:1294-1296.
307. Myhr K.M., Mellgren S.I. Corticosteroids in the treatment of multiple sclerosis. Acta. Neurol. Scand. Suppl. 2009, 73-80.
308. Burton J.M., O'Connor P.W., Hohol M., Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst. Rev. 2009, CD006921.
309. Baschant U., Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol. 2010, 120:69-75.
310. Chan J., Ban E.J., Chun K.H., Wang S., McQualter J., Bernard C., et al. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 2008, 41:405-413.
311. Beer T.M. Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol. Oncol. 2003, 21:399-405.
312. Zerwekh J.E., Pak C.Y., Kaplan R.A., McGuire J.L., Upchurch K., Breslau N., et al. Pathogenetic role of 1 alpha,25-dihydroxyvitamin D in sarcoidosis and absorptive hypercalciuria: different response to prednisolone therapy. J. Clin. Endocrinol. Metab. 1980, 51:381-386.
313. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
314. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
315. Fox E.J. Management of worsening multiple sclerosis with mitoxantrone: a review. Clin. Ther. 2006, 28:461-474.
316. Chiao E., Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr. Med. Res. Opin. 2009, 25:1445-1454.
317. Kunze A.M., Gunderson B.W., Gleason P.P., Heaton A.H., Johnson S.V. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs - pharmacy and medical benefit spending from 2004 through 2007. J. Manag. Care Pharm. 2007, 13:799-806.
318. Prescott J.D., Factor S., Pill M., Levi G.W. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J. Manag. Care Pharm. 2007, 13:44-52.
319. Kobelt G., Berg J., Atherly D., Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006, 66:1696-1702.
320. Kobelt G., Berg J., Lindgren P., Fredrikson S., Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiat. 2006, 77:918-926.
321. Holmoy T. Vitamin D status modulates the immune response to Epstein Barr virus: synergistic effect of risk factors in multiple sclerosis. Med. Hypoth. 2008, 70:66-69.